Foster & Motley Inc. raised its stake in Johnson & Johnson (NYSE:JNJ) by 9.4% during the second quarter, Holdings Channel reports. The firm owned 38,194 shares of the company’s stock after buying an additional 3,286 shares during the period. Foster & Motley Inc.’s holdings in Johnson & Johnson were worth $4,633,000 as of its most recent SEC filing.
Other institutional investors have also modified their holdings of the company. Americafirst Capital Management LLC purchased a new stake in Johnson & Johnson during the second quarter valued at about $101,000. INR Advisory Services LLC purchased a new stake in Johnson & Johnson during the second quarter valued at about $150,000. Capital Asset Advisory Services LLC purchased a new stake in Johnson & Johnson during the second quarter valued at about $202,000. NewSquare Capital LLC raised its stake in Johnson & Johnson by 4.9% in the second quarter. NewSquare Capital LLC now owns 1,791 shares of the company’s stock valued at $217,000 after buying an additional 83 shares in the last quarter. Finally, Shayne & CO. LLC purchased a new stake in Johnson & Johnson during the second quarter valued at about $219,000. Hedge funds and other institutional investors own 65.32% of the company’s stock.
Shares of Johnson & Johnson (NYSE:JNJ) traded up 0.59% during trading on Monday, hitting $119.94. The stock had a trading volume of 1,819,969 shares. The stock has a market cap of $328.14 billion, a price-to-earnings ratio of 22.35 and a beta of 0.62. The company’s 50 day moving average price is $118.85 and its 200 day moving average price is $117.07. Johnson & Johnson has a 12 month low of $94.12 and a 12 month high of $126.07.
Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Tuesday, July 19th. The company reported $1.74 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.68 by $0.06. Johnson & Johnson had a return on equity of 24.70% and a net margin of 20.97%. The firm earned $18.50 billion during the quarter, compared to analysts’ expectations of $17.98 billion. Equities research analysts expect that Johnson & Johnson will post $6.69 earnings per share for the current fiscal year.
Several equities research analysts recently issued reports on JNJ shares. Goldman Sachs Group Inc. set a $121.00 target price on shares of Johnson & Johnson and gave the stock a “neutral” rating in a report on Monday, June 13th. Jefferies Group reissued a “hold” rating and issued a $109.00 target price (up from $108.00) on shares of Johnson & Johnson in a report on Tuesday, June 14th. Barclays PLC reissued an “overweight” rating and issued a $125.00 target price (up from $120.00) on shares of Johnson & Johnson in a report on Sunday, July 10th. Wells Fargo & Co. reissued a “buy” rating on shares of Johnson & Johnson in a report on Monday, July 11th. Finally, Royal Bank Of Canada increased their target price on shares of Johnson & Johnson from $125.00 to $133.00 and gave the stock an “outperform” rating in a report on Wednesday, July 20th. Two analysts have rated the stock with a sell rating, eleven have given a hold rating and eleven have assigned a buy rating to the stock. The stock currently has an average rating of “Hold” and an average target price of $120.19.
In other Johnson & Johnson news, CAO Ronald A. Kapusta sold 2,935 shares of the company’s stock in a transaction on Friday, July 22nd. The stock was sold at an average price of $125.01, for a total value of $366,904.35. Following the completion of the sale, the chief accounting officer now directly owns 28,660 shares in the company, valued at approximately $3,582,786.60. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, VP Dominic J. Caruso sold 41,146 shares of the company’s stock in a transaction on Tuesday, July 26th. The shares were sold at an average price of $125.01, for a total value of $5,143,661.46. Following the completion of the sale, the vice president now owns 157,819 shares of the company’s stock, valued at $19,728,953.19. The disclosure for this sale can be found here. Corporate insiders own 0.11% of the company’s stock.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company’s segments include Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women’s health and wound care markets.
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.